(NASDAQ: EVAX) Evaxion Biotech A's forecast annual revenue growth rate of 817.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Evaxion Biotech A's revenue in 2024 is $73,000.On average, 1 Wall Street analysts forecast EVAX's revenue for 2024 to be $530,568,920, with the lowest EVAX revenue forecast at $530,568,920, and the highest EVAX revenue forecast at $530,568,920. On average, 1 Wall Street analysts forecast EVAX's revenue for 2025 to be $1,332,864,923, with the lowest EVAX revenue forecast at $1,332,864,923, and the highest EVAX revenue forecast at $1,332,864,923.
In 2026, EVAX is forecast to generate $4,622,392,227 in revenue, with the lowest revenue forecast at $4,622,392,227 and the highest revenue forecast at $4,622,392,227.